Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is listed today as Bolt Biotherapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
6 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2021 | $15 M | No. 6 | $10 to $50 million | equity | SEC | |
| Jun 2020 | $94 M | No. 5 | $50 to $250 million | equity | SEC | |
| Jul 2019 | $40 M | No. 4 | $10 to $50 million | equity | SEC | |
| Jul 2018 | $13 M | No. 3 | $10 to $50 million | equity | SEC | |
| Feb 2018 | $6 M | No. 2 | $2 to $10 million | equity | SEC | |
| Sep 2016 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Bolt Biotherapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2021).
SEC Form D · Jun 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2021
That is all the official record says: Bolt Biotherapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Bolt Biotherapeutics, Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Sofinnova Management X, L.L.C. | Fund or asset manager | not stated | not stated | Held Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Sofinnova Venture Partners X, L.P. | Venture capital | not stated | not stated | Held Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Vivo Capital Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Vivo Capital Surplus Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Vivo Capital VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Vivo Panda Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Vivo Panda, LLC | Other | not stated | not stated | Held Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 17 investors.
Largest shareholders today
Institutions holding Bolt Biotherapeutics, Inc. shares, as of Sep 30, 2026.
- Sofinnova Investments, Inc.$1 M7.15%
- Renaissance Technologies LLC$0 M4.82%
- Vivo Capital, LLC$0 M3.76%
- T3 Companies, LLC$0 M1.97%
- Board of Trustees of The Leland Stanford Junior University$0 M1.87%
- Pfizer Inc$0 M1.63%
- Lynx1 Capital Management LP$0 M1.60%
- Nano Cap New Millennium Growth Fund L P$0 M1.43%
- Citadel Advisors LLC$0 M0.95%
- Susquehanna International Group, LLP$0 M0.87%
- Shay Capital LLC$0 M0.86%
- Geode Capital Management, LLC$0 M0.82%
- Vanguard Fiduciary Trust Co$0 M0.81%
- BlackRock, Inc.$0 M0.50%
- Vanguard Capital Management LLC$0 M0.37%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Dornan | Executive officer | Jun 2021 |
| Edith Perez | Executive officer | Jun 2021 |
| Grant Yonehiro | Executive officer | Jun 2021 |
| Randall Schatzman | Executive officer | Jun 2021 |
| William Quinn | Executive officer | Jun 2021 |
| Edgar Engleman | Executive officer | Jul 2019 |
| Grant G. Yonehiro | Executive officer | Aug 2018 |
| Edgar G. Engleman | Executive officer | Feb 2018 |
| Reiner Laus | Executive officer | Sep 2016 |
| Ashish Khanna | Director | Jun 2021 |
| Edgar Engleman | Director | Jun 2021 |
| James Healy | Director | Jun 2021 |
| Kathleen LaPorte | Director | Jun 2021 |
| Mahendra Shah | Director | Jun 2021 |
| Peter Moldt | Director | Jun 2021 |
| Randall Schatzman | Director | Jun 2021 |
| Richard Miller | Director | Jun 2021 |
| Ashish G. Khanna | Director | Aug 2018 |
| Edgar G. Engleman | Director | Aug 2018 |
| Mahendra G. Shah | Director | Aug 2018 |
| Peter G. Moldt | Director | Aug 2018 |
| Ken G. Harrison | Director | Feb 2018 |
| Peter G. Bisgaard | Director | Sep 2016 |
| Reiner Laus | Director | Sep 2016 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.